Literature DB >> 25483038

Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer.

Kotaro Kiga1, Yoko Fukuda-Yuzawa, Masanobu Tanabe, Shoji Tsuji, Chihiro Sasakawa, Taro Fukao.   

Abstract

Overexpression of SIRT1 is frequently observed in various types of cancers, suggesting its potential role in malignancies. However, the molecular basis of how SIRT1 is elevated in cancer is less understood. Here we show that cancer-related SIRT1 overexpression is due to evasion of Sirt1 mRNA from repression by a group of Sirt1-targeting microRNAs (miRNAs) that might be robustly silenced in cancer. Our comprehensive library-based screening and subsequent miRNA gene profiling revealed a housekeeping gene-like broad expression pattern and strong CpG island-association of the Sirt1-targeting miRNA genes. This suggests aberrant CpG DNA methylation as the mechanistic background for malignant SIRT1 elevation. Our work also provides an example where epigenetic mechanisms cause the group-wide regulation of miRNAs sharing a common key target.

Entities:  

Keywords:  3′UTR, 3′ untranslated region; 5-Aza-dC, 5-aza-2’-deoxycytidine; CGIs, CpG islands; DNA methylation; E2F1, E2F transcription factor 1; FOXO, forkhead box O; HIC1, hypermethylated in cancer 1; LXR, liver X receptor; MicroRNA; MyoD, myogenic differentiation 1; NAD, nicotinamide adenine dinucleotide; NF-κB, nuclear factor kappa-B; OVCA1, ovarian cancer-associated gene 1 protein; OVCA2, ovarian cancer-associated gene 2 protein; PARP, poly(ADP-ribose) polymerase-1; PGC-1α, peroxisome proliferative activated receptor, gamma, coactivator 1 alpha; PUMA, p53-upregulated modulator of apoptosis; SIRT1; SIRT1, sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae); SMG6, smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans); Sir2, Silent information regulator 2; cancer; epigenetics; p53, protein 53; pri-miRNA, primary miRNA

Mesh:

Substances:

Year:  2014        PMID: 25483038      PMCID: PMC4615778          DOI: 10.4161/rna.32093

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  26 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 2.  How are cancer associated genes activated or inactivated?

Authors:  L M Wiedemann; G J Morgan
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

3.  miR-212 and miR-132 are dispensable for mouse mammary gland development.

Authors:  Hiroyuki Kayo; Kotaro Kiga; Yoko Fukuda-Yuzawa; Sebastian Hedlund; Kazuyoshi Murakami; Inti A De La Rosa-Velazquez; Tokuhiro Kimura; Kouji Shimoda; Masanobu Tanabe; Taro Fukao
Journal:  Nat Genet       Date:  2014-08       Impact factor: 38.330

4.  Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance.

Authors:  An Ning Feng; Li Hua Zhang; Xiang Shan Fan; Qin Huang; Qing Ye; Hong Yan Wu; Jun Yang
Journal:  Int J Surg Pathol       Date:  2011-08-24       Impact factor: 1.271

Review 5.  Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer.

Authors:  Yolanda Olmos; Jan J Brosens; Eric W-F Lam
Journal:  Drug Resist Updat       Date:  2010-12-30       Impact factor: 18.500

6.  Negative control of p53 by Sir2alpha promotes cell survival under stress.

Authors:  J Luo; A Y Nikolaev; S Imai; D Chen; F Su; A Shiloh; L Guarente; W Gu
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

7.  Balance between SIRT1 and DBC1 expression is lost in breast cancer.

Authors:  Ji-Youn Sung; Ranah Kim; Ja-Eun Kim; Juhie Lee
Journal:  Cancer Sci       Date:  2010-03-24       Impact factor: 6.716

Review 8.  CpG island methylator phenotype in cancer.

Authors:  Jean-Pierre Issa
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

9.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

10.  SIRT1 is significantly elevated in mouse and human prostate cancer.

Authors:  Derek M Huffman; William E Grizzle; Marcas M Bamman; Jeong-su Kim; Isam A Eltoum; Ada Elgavish; Tim R Nagy
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

View more
  6 in total

1.  The identification of specific methylation patterns across different cancers.

Authors:  Chunlong Zhang; Hongyan Zhao; Jie Li; Hongbo Liu; Fang Wang; Yanjun Wei; Jianzhong Su; Dongwei Zhang; Tiefu Liu; Yan Zhang
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

2.  Reversible modulation of SIRT1 activity in a mouse strain.

Authors:  Katherine V Clark-Knowles; Xiaohong He; Karen Jardine; Josée Coulombe; Danielle Dewar-Darch; Annabelle Z Caron; Douglas A Gray; Michael W McBurney
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

Review 3.  MicroRNAs as regulators and mediators of forkhead box transcription factors function in human cancers.

Authors:  Chen Li; Kai Zhang; Jing Chen; Longbang Chen; Rui Wang; Xiaoyuan Chu
Journal:  Oncotarget       Date:  2017-02-14

4.  SIRT1 Deficiency, Specifically in Fibroblasts, Decreases Apoptosis Resistance and Is Associated with Resolution of Lung-Fibrosis.

Authors:  Raanan Bulvik; Raphael Breuer; Mona Dvir-Ginzberg; Eli Reich; Neville Berkman; Shulamit B Wallach-Dayan
Journal:  Biomolecules       Date:  2020-07-02

5.  PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD+ levels and increasing SIRT1 activity.

Authors:  Siyuan Zha; Zhen Li; Qing Cao; Fei Wang; Fang Liu
Journal:  Stem Cell Res Ther       Date:  2018-08-23       Impact factor: 6.832

Review 6.  Trending topics of SIRT1 in tumorigenicity.

Authors:  Liz M Garcia-Peterson; Xiaoling Li
Journal:  Biochim Biophys Acta Gen Subj       Date:  2021-06-18       Impact factor: 4.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.